Combination therapy for chronic active Epstein-Barr virus disease
Treatments studied
Part of Cancer, Immune system & allergy, Infections clinical trials.
This trial tests two drugs, golidocitinib and selinexor, given together to treat chronic active Epstein-Barr virus disease (CAEBVD). The goal is to see if this combination can help control the disease better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have been diagnosed with chronic active Epstein-Barr virus disease based on current guidelines.
- You must be well enough to perform daily activities without help (ECOG score 0 or 1).
- Your liver and kidney function must be within certain limits (blood tests will confirm).
- Your blood counts must meet minimum levels (neutrophils, platelets, and hemoglobin).
- You cannot have other cancers, active infections, or have had certain prior treatments like a JAK inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs for people whose intestinal disease is linked to the Epstein-Barr virus (EBV). It aims to see if this treatment can help control the disease and improve outcomes.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests a combination of drugs (PD-1 inhibitor, tenofovir, chidamide, and lenalidomide) to treat diseases caused by the Epstein-Barr virus (EBV). The goal is to see if this combination can reduce the virus and improve symptoms.
This is an early-stage study testing a new immune-based treatment for people with conditions caused by the Epstein-Barr virus (EBV), such as chronic active EBV or post-transplant lymphoproliferative disease. The study aims to see if the treatment is safe and can help control the disease.
This study tests a combination of four drugs (an immunotherapy called a PD-1 inhibitor, an antiviral drug called tenofovir, and two other targeted therapies) for people whose EBV-related lymphoma has come back or not improved after treatment. The goal is to see if this combination can control the disease and help patients live longer.
Hear when a new EBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.